Home \ Why Mexidol®?

Why Mexidol®?

Peculiarities of managing patients with CVD against the background of metabolic syndrome and diabetes mellitus

Polymorphism of clinical manifestations of CIM. Pathogenetic therapy

Frail patient with cerebrovascular disease

Cognitive impairment in arterial hypertension

Actual strategies for neuroprotement in glaucoma

Management of patients with chronic cerebrovascular pathology against the background of metabolic syndrome and diabetes mellitus

Traumatic brain injury: issues of practical interaction between a neurologist and a psychiatrist

Therapeutic portrait of a patient with memory disorders

Glaucoma as an interdisciplinary problem

Alcoholism as an interdisciplinary problem

Time codes:

01:02
History of the drug Mexidol®
01:40
The mechanism of action of the drug Mexidol®
03:03
Mexidol® - pharmacological effects
03:54
Clinical effects and safety of Mexidol®
04:30
Security Profile
05:09
The optimal dose and duration of intravenous infusion and intramuscular injection
05:50
Mexol 125 mg, Mexidol® Fort 250 mg transition
06:20
Evidence base of the effectiveness of Mexidol
06:45
The results of the study of Epic
08:16
Clinical recommendations
09:40
Differences in Mexidol® and analogues.

Schukin Ivan Aleksandrovich - Ph.D., Associate Professor of the Department of Neurology, Neurosurgery and Medical Genetics LF RNIMU named after N.I. Pirogov

Announcement:

Schukin Ivan Alexandrovich - candidate of medical sciences, associate professor of the Department of Neurology of the Russian State Medical University, answers the main questions about the drug Mexol®. Why is Mexidol® so widely prescribed and popular among doctors and patients? What pharmacological and clinical effects does it have? What is the evidence base and methods of using the drug Mexidol®? Let's figure it out!

Find out more in the video " Mexidol® - the standard of antioxidant neurocytoprotection ."

All video next video

Peculiarities of managing patients with CVD against the background of metabolic syndrome and diabetes mellitus

Polymorphism of clinical manifestations of CIM. Pathogenetic therapy

Frail patient with cerebrovascular disease

Cognitive impairment in arterial hypertension

Actual strategies for neuroprotement in glaucoma

Management of patients with chronic cerebrovascular pathology against the background of metabolic syndrome and diabetes mellitus

Traumatic brain injury: issues of practical interaction between a neurologist and a psychiatrist

Therapeutic portrait of a patient with memory disorders

Glaucoma as an interdisciplinary problem

Alcoholism as an interdisciplinary problem

Time codes:

01:02
History of the drug Mexidol®
01:40
The mechanism of action of the drug Mexidol®
03:03
Mexidol® - pharmacological effects
03:54
Clinical effects and safety of Mexidol®
04:30
Security Profile
05:09
The optimal dose and duration of intravenous infusion and intramuscular injection
05:50
Mexol 125 mg, Mexidol® Fort 250 mg transition
06:20
Evidence base of the effectiveness of Mexidol
06:45
The results of the study of Epic
08:16
Clinical recommendations
09:40
Differences in Mexidol® and analogues.

Block of articles on this topic

Mexidol: a spectrum of pharmacological effects

Author:
Voronina T.A.

Nii pharmacology named after V.V. Zakusov RAMS, Moscow

Original and reproduced drugs: what do the clinician need to know?

Author:
A.V. Schulkin, A.A. Filimonova
FSBEI in the Ryazan State Medical University of the Ministry of Health of Russia, Ryazan, Russia

The results of a randomized double blind multicenter placebo-controlled in parallel groups of the study and safety of Mexidol with prolonged consistent therapy in patients in the acute and early recovery periods

Registered on ClinicalTrials

L.V. Stakhovskaya ¹ , N.A. Shamalov ¹ , DR Khasanova ² , E.V. Melnikova ³ , A.S. Agafin ⁴ , K.V. Golikov ⁵ , E.I. Bogdanov ⁶ , A.A. Yakupova ⁶ , L.V. Roshkovskaya ⁷ , L.V. Lukin ⁸ , T.M. Lokstanova ⁹ , I.E. Patrunenova ¹⁰ , L.A. Shchepankevich ¹¹

¹ Research Institute of Cerebrovascular Pathology and Stroke of the Federal State Budgetary Institution “Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia;
² Igauz "Interregional Clinical and Diagnostic Center", Kazan, Russia;
³ St. Petersburg GBUZ "City Hospital No. 26", St. Petersburg, Russia;
⁴ St. Petersburg GBUZ "City Hospital No. 40 of the Resort Administrative District", St. Petersburg, Russia;
⁵ St. Petersburg GBUZ "City multidisciplinary hospital No. 2", St. Petersburg, Russia;
⁶ FSBEI in Kazan State Medical University of the Ministry of Health of Russia, Kazan, Russia;
⁷ St. Petersburg GBUZ "Nikolaev Hospital", St. Petersburg, Russia;
⁸ GBUZ "Vsevolozhsk Clinical Interdistrict Hospital", Leningrad Region, Russia;
⁹ Mubz "City Clinical Hospital No. 1 named after N.I. Pirogov ", Samara, Russia;
¹⁰ GBUZ "Samara Regional Clinical Hospital named after V.D. Seredavina ”, Samara, Russia;
¹¹ FGBNU "Scientific Institute of Experimental and Clinical Medicine", Novosibirsk, Russia.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2017, No. 3, issue 2

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com